Not Signed In - Dynavax Reports Interim, One-Year Data From Ragweed Allergy Trial At AAAAI
Sat, 24 Feb 2007 08:00 AM EST
... Dynavax Technologies Corporation (Nasdaq: DVAX) today reported interim data from the first year of its two-year ragweed allergy trial known as DARTT, including a prespecified regional analysis of sites that clearly showed a therapeutic benefit of TOLAMBA in the Midwest. These data and the results of an in-depth analysis of 716 evaluable patients at 30 U.S. [click link for full article] ...
Related Topics
- Clinical Trials
- Data & Statistics
- Data Analysis
- Allergy
- National Data
- Latex Allergy
- Food Allergy
- Pollen
- Mining
- Clemastine
- This Is Your Year
- Asthma
- Shellfish
- Diphenhydramine Liquid
- U.S.- Japan Cooperative Medical Science Program: Sixth Five Year Report
- Well Baby Reports
- Logging
- Tuberculosis Surveillance Reports
- Chronic Disease At A Glance Reports
- Chronic Disease Notes And Reports
email this page
print this page
bookmark this page
feedback on this page
